The 36-month beta value for ZVSA is at 0.46. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ZVSA is 2.50M, and currently, shorts hold a 1.78% of that float. The average trading volume for ZVSA on March 12, 2025 was 891.43K shares.
ZVSA) stock’s latest price update
ZyVersa Therapeutics Inc (NASDAQ: ZVSA)’s stock price has decreased by -11.62 compared to its previous closing price of 0.95. However, the company has seen a -10.99% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-12 that WESTON, Fla., March 12, 2025 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights newly published data demonstrating that NLRP3 Inhibition attenuates development of AD pathology (buildup of Aβ) and neuroinflammation in a mouse model of AD, thereby attenuating disease progression.
ZVSA’s Market Performance
ZVSA’s stock has fallen by -10.99% in the past week, with a monthly drop of -31.12% and a quarterly drop of -17.61%. The volatility ratio for the week is 14.57% while the volatility levels for the last 30 days are 9.11% for ZyVersa Therapeutics Inc The simple moving average for the last 20 days is -23.94% for ZVSA stock, with a simple moving average of -64.68% for the last 200 days.
ZVSA Trading at -31.65% from the 50-Day Moving Average
After a stumble in the market that brought ZVSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.76% of loss for the given period.
Volatility was left at 9.11%, however, over the last 30 days, the volatility rate increased by 14.57%, as shares sank -33.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.14% lower at present.
During the last 5 trading sessions, ZVSA fell by -11.59%, which changed the moving average for the period of 200-days by -81.07% in comparison to the 20-day moving average, which settled at $1.1045. In addition, ZyVersa Therapeutics Inc saw -20.72% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ZVSA
Current profitability levels for the company are sitting at:
- -617.08 for the present operating margin
- -0.0 for the gross margin
The net margin for ZyVersa Therapeutics Inc stands at -155140.06. The total capital return value is set at -1.22. Equity return is now at value -159.59, with -81.61 for asset returns.
Currently, EBITDA for the company is -107.74 million with net debt to EBITDA at 0.01. When we switch over and look at the enterprise to sales, we see a ratio of 128.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.03.
Conclusion
In conclusion, ZyVersa Therapeutics Inc (ZVSA) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
